MA27072A1 - Formes cristallines anhydres de gabapentine nouvelles - Google Patents

Formes cristallines anhydres de gabapentine nouvelles

Info

Publication number
MA27072A1
MA27072A1 MA27606A MA27606A MA27072A1 MA 27072 A1 MA27072 A1 MA 27072A1 MA 27606 A MA27606 A MA 27606A MA 27606 A MA27606 A MA 27606A MA 27072 A1 MA27072 A1 MA 27072A1
Authority
MA
Morocco
Prior art keywords
gabapentin
gabapentine
crystalline forms
anhydrous
forms
Prior art date
Application number
MA27606A
Other languages
English (en)
Inventor
Linna R Chen
Claude Jeffrey Calvitt
Suresh R Babu
Brian TOBIAS
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MA27072A1 publication Critical patent/MA27072A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DEPOSANT Société dite: WARNER-LAMBERT COMPANY LLC REVENDICATION DE PRIORITES US 9 Octobre 2001 60/328,375 US 25 Septembre 2002 10/256,155 Voir en annexe le titre de l'invention et le texte de l'abrégé Formes cristallines anhydres de gabapentine nouvelles Il est décrit des formes anhydres cristallines nouvelles de gabapentine formées à partir de monohydrate de gabapentine. Les formes cristallines nouvelles présentent des avantages dans la production de l'agent thérapeutique.
MA27606A 2001-10-09 2004-04-05 Formes cristallines anhydres de gabapentine nouvelles MA27072A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32837501P 2001-10-09 2001-10-09
US10/256,155 US6800782B2 (en) 2001-10-09 2002-09-25 Anhydrous crystalline forms of gabapentin

Publications (1)

Publication Number Publication Date
MA27072A1 true MA27072A1 (fr) 2004-12-20

Family

ID=26945177

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27606A MA27072A1 (fr) 2001-10-09 2004-04-05 Formes cristallines anhydres de gabapentine nouvelles

Country Status (27)

Country Link
US (1) US6800782B2 (fr)
EP (1) EP1463712A1 (fr)
JP (1) JP2005505594A (fr)
KR (1) KR20050033525A (fr)
CN (1) CN1568305A (fr)
AP (1) AP2004003025A0 (fr)
BG (1) BG108702A (fr)
BR (1) BR0213156A (fr)
CA (1) CA2462331A1 (fr)
CO (1) CO5570697A2 (fr)
CZ (1) CZ2004416A3 (fr)
EA (1) EA006557B1 (fr)
GE (1) GEP20063936B (fr)
HR (1) HRP20040408A2 (fr)
HU (1) HUP0401782A3 (fr)
IL (1) IL161099A0 (fr)
IS (1) IS7195A (fr)
MA (1) MA27072A1 (fr)
MX (1) MXPA04003301A (fr)
NO (1) NO20041370L (fr)
NZ (1) NZ531993A (fr)
OA (1) OA12665A (fr)
PL (1) PL368117A1 (fr)
RS (1) RS28204A (fr)
SK (1) SK1572004A3 (fr)
TN (1) TNSN04055A1 (fr)
WO (1) WO2003031391A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070043236A1 (en) * 2003-05-19 2007-02-22 Chandiran Thakashina M Process for preparation of gabapentin
WO2004106281A1 (fr) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Gabapentine cristallin
WO2004110342A2 (fr) * 2003-06-12 2004-12-23 Matrix Laboratories Ltd Nouveau polymorphe de gabapentine et sa conversion en gabapentine de forme ii
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
ITMI20040579A1 (it) * 2004-03-25 2004-06-25 Zambon Spa Processo di preparazione di gabapentina
WO2010023694A2 (fr) * 2008-09-01 2010-03-04 Hikal Ltd Formes cristallines de la gabapentine et leur procédé
CN104649921B (zh) * 2015-01-14 2016-09-28 天津大学 一种加巴喷丁与己二酸共晶及其制备方法
CN116693410B (zh) * 2023-06-08 2024-06-07 浙江竹子制药有限公司 一种粒径可控的加巴喷丁制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
JPS62247160A (ja) * 1986-03-31 1987-10-28 Aisin Seiki Co Ltd スタ−リングエンジンの始動装置
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
US4960931A (en) * 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
DE3928184A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
IL119890A (en) 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
ES2137137B1 (es) 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.

Also Published As

Publication number Publication date
BG108702A (en) 2005-05-31
HRP20040408A2 (en) 2004-10-31
GEP20063936B (en) 2006-10-10
HUP0401782A2 (hu) 2005-10-28
MXPA04003301A (es) 2004-07-23
HUP0401782A3 (en) 2006-01-30
EA200400417A1 (ru) 2004-10-28
EP1463712A1 (fr) 2004-10-06
IL161099A0 (en) 2004-08-31
BR0213156A (pt) 2004-09-14
CO5570697A2 (es) 2005-10-31
US20030092933A1 (en) 2003-05-15
RS28204A (sr) 2006-12-15
NO20041370L (no) 2004-04-01
CZ2004416A3 (cs) 2005-03-16
CN1568305A (zh) 2005-01-19
TNSN04055A1 (fr) 2006-06-01
PL368117A1 (en) 2005-03-21
OA12665A (en) 2006-06-19
KR20050033525A (ko) 2005-04-12
SK1572004A3 (sk) 2005-03-04
AP2004003025A0 (en) 2004-06-30
CA2462331A1 (fr) 2003-04-17
US6800782B2 (en) 2004-10-05
WO2003031391A1 (fr) 2003-04-17
NZ531993A (en) 2006-09-29
IS7195A (is) 2004-03-23
JP2005505594A (ja) 2005-02-24
EA006557B1 (ru) 2006-02-24

Similar Documents

Publication Publication Date Title
AU2002356759A1 (en) 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
MA28003A1 (fr) [1,8] naphtyridine-2-ones et composes apparentes pour le traitement de la schizophrenie
EP2311489A3 (fr) Formulation des solutions contenant des anti-corps comportant un sucre comme stabilisateur
WO2008068615A8 (fr) Formes cristallines de l'acide (3s)-3-[n-(n'-(2-tert-butyphényl)oxamyl)alaninyl]amino-5-(2',3',5',6'-tétrafluorophénoxy)-4-oxopentanoïque
MA27072A1 (fr) Formes cristallines anhydres de gabapentine nouvelles
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
MA27133A1 (fr) Nouvelles formes polymorphes cristallines d'hydrochlorure de lercanidipine et procede de fabrication associe
WO2003066594A3 (fr) Inhibiteurs de l'integrine $g(a)v$g(b)6
MA27169A1 (fr) Metabolites de l'acide (3-{ [(4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetique
FR2834896B1 (fr) Composition pharmaceutique orodispersible d'ivabradine
WO2003059323A3 (fr) Sels stables d'acide o-acetylsalicylique contenant des acides amines ii basiques
ITMI20021755A1 (it) Processo e nuovi intermedi per la preparazione di steroidi ad attivita' progestinica.
ITMI20030063A1 (it) Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
WO2004048381A3 (fr) Nouveaux composes de pyrazoloazepine utilises en tant qu'agents pharmaceutiques
ITMI20030778A1 (it) Procedimento per la preparazione enzimatica dell'aroma di vaniglia.
ITMI20000837A0 (it) Processo per la sintesi di cefoperazone sodico ad elevata cristallimita'
BR0012547A (pt) ésteres oligomerécos de ácido bisclorocarbÈnico obtidos de bisfenóis cicloalifáticos selecionados e outros bisfenóis
DE60200184D1 (de) Optisch aktive Verbindung und Flüssigkristallzusammensetzung enthaltend die Verbindung
IT1320401B1 (it) Procedimento per la fabbricazione di componenti di un'ossatura ecomponenti di ossatura.
ITMI20030176A1 (it) Procedimento per la preparazione di gabapentina "forma ii" pura
MY129370A (en) New anhydrous crystalline forms of gabapentin
ITRM20020357A1 (it) Composizione liquida per la somministrazione orale di lorazepam.
DE60200271D1 (de) Optisch aktive Verbindung und Flüssigkristallzusammensetzung enthaltend die Verbindung
AU2003248351A1 (en) Crystalline anhydrous and monohydrate benzoate salts of (2's,3s)-3-hydroxy-n-{2{n-methyl-n-4-(n-propylamino-carbonyl)phenyl)amino-2-phenyl}-ethylpyrrolidine
DE60128077D1 (de) Verbindung für die Behandlung von atherosclerotischen und thrombotischen Erkrankungen